group database to report the association between preoperative and an angiotensin system blocker use and the risk of AKI postoperatively. They report that current and former users are at increased risk of postoperative AKI. The studies overall well done and reported cleanly, with a adequate discussion of the limitations. The following suggestions are provided to help readers put things into the proper perspective.
1. From table 1, it is obvious that former and current users of these drugs are different than nonusers. Given the numbers involved, would it be possible to consider propensity score matching as a stronger design? Residual confounding would still be a concern, however this study design with PS matching would give more confidence. It can be seen from the analysis, that the risk of AKI is about 40% higher and this is attenuated to about 15 to 20% after adjustment. Hence the question of residual confounding, as identified by the authors also, is a big one.
2.The outcome definition is based on a change in creatinine within 7 days, which is different than the usual 48 to 72 hours. Though not presented, it would be interesting to see the severity of acute kidney injury among former or current users compared to nonusers. Arguably, the soft definition of AKI, which is a biochemical change, is not meaningful. See the review by Steve Coca which discusses the issue of her rising creatinine as compared to true tubular injury. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5989667/ 3. Most importantly, though the abstract and the article summary are measured in the conclusions, the interpretation section of the manuscript overreaches in the recommendation. In the absence of any randomized controlled trial, this reviewer would not put any recommendations about changing or stopping these drugs preoperatively. Stopping these drugs may have unintended consequences, including an increase in blood pressure, and decompensation of beneficial effects in patients for whom there is a strong indication to take them.
Minor issues: 4. The very first sentence in the introduction about the role of ACE inhibitors is a bit of an understatement, considering the hemodynamic effects of these drugs 5. In the second paragraph of the introduction, with the sentence starting "AKI is defined as", it would be more useful to also state the definition of AKI used in the citation #5.
REVIEWER
Laurie Tomlinson London School of Hygiene and Tropical Medicine REVIEW RETURNED 01-Aug-2019
GENERAL COMMENTS
This is a straightforward and well-written paper that looks at the association between use of ACEI/ARB before colorectal surgery and the development of AKI. There are limitations, but these are inherent to using observational data to address this question and are understood by the authors I have relatively minor comments to make where I think the authors could strengthen the paper.
1. 'PCr' suggests protein: creatinine ratio to me. Is there a reason why they can't just say 'creatinine'? 2. If no baseline creatinine was available I think the authors imputed it "If neither measurement was available, it was estimated using the Modification of Diet in Renal Disease (MRDR) formula as recommended by the RIFLE, AKIN and KDIGO consensus criteria [6, 26] ." As I suspect the authors know this practice is not widely accepted in AKI research (eg https://onlinelibrary.wiley.com/doi/abs/10.1111/apha.127 63). I would imagine that not having a baseline creatinine is strongly associated with the covariates. I think they dropped these patients with imputed baseline in their complete case analysis and reassuringly this shows similar outcomes. My preference would be to not include these patients at all in the main analysis as this is least prone to misclassification, and use this 'imputed' analysis as a secondary analysis. However, I don't feel it is necessary to insist on this but the authors need to be explicit about what the GFR they back calculated was, how many patients this involved, and at least do a sensitivity analysis dropping these patients (separately from dropping those with imputed baseline CKD status). 3. Similarly, "Chronic kidney disease (CKD), a strong predictor for AKI [6] , was identified using PCr measurements from LAKBA [22] and defined as an estimated glomerular filtration rate (eGFR) <60 ml/min/1.73 m2 lasting at least three months within two years before CRC surgery." Here my preference would be to use impaired eGFR as the adjusting variable as there is less bias than for people who have two measures of creatinine to define CKD -and use CKD as the authors have defined it as a sensitivity analysis. Again, not insisting the authors do this, but is it correct that 80% had 2 measures? How many had only 1? 4. "Multiple imputations of the covariates (CKD, smoking, BMI, weekly alcohol intake) with missing data (~20%) were performed using the mi impute chained procedure in Stata 13.1 to create five imputed datasets" Please could the authors state the assumptions they used to do the imputation and justify it briefly. I would say that MCAR does not apply and MAR is tenuous. However, the complete case analysis is reassuring. As above, the authors should show the no baseline creatinine to define AKI and no CKD status (and the no imputed data) as separate analyses in the supp appendix, both with the numbers included. 5. What is lovely about your study is that you show that it is the indication for the ACEI/ARB, or the pathology associated with that indication, that causes the AKI, not the drug itself (as the association of AKI is basically the same for users and ex-users). I would say this directly rather than 'We cannot rule out that confounding by indication may also have contributed to the results.'. Similarly, you state 'we cannot rule out that the lack of difference in association for current and former user may be explained by unmeasured confounding by indication and residual confounding. For example, we lack data on blood pressure, fluid balance and administration, and timing of other postoperative complications." This is not clear and it would be good to give a direct example of how confounding would cause AKI. However, I would argue that it is not confounding, it is a causal effect, just not due to the drug. 6. In terms of the discussion you cite a lot of observational papers but these are all limited to examine this question, as you have also demonstrated. I hate to be the reviewer that suggests self-citation (so you don't have to!) but the best evidence about whether ACEI/ARB cause AKI after interventions comes from RCTs. This is very limited but is summarised here: https://bmjopen.bmj.com/content/bmjopen/7/4/e012674 .full.pdf and also there is evidence that it is the comorbidities and not the drugs that lead to the association with AKI here: https://bmjopen.bmj.com/content/6/12/e012690. The broader argument is summarised here: https://cjasn.asnjournals.org/content/14/4/617/tabarticle-info. But as I say, don't feel you should cite any of these, it's just to back up my viewpoint!! 7. I think you are wise to move towards framing your argument in terms of 'this is a high risk group for AKI, they should be monitored closely' and I would broaden that rather than trying to blame the drugs. Could you suggest some absolute risks based on your data? X% of people develop AKI after surgery, X% of people having the surgery are taking ACEI/ARB so have a 20% increased risk so for every 100 people having the surgery x more will develop AKI….
VERSION 1 -AUTHOR RESPONSE
Reviewer: 1 Reviewer Name: Jung Tak Park Institution and Country: Yonsei University, Korea Please state any competing interests or state 'None declared': none Please leave your comments for the authors below In this manuscript by Slagelse et al, the authors have shown that RAAS blockade users are at an increased risk of post-operative AKI among those undergoing colorectal cancer surgery. In order to arrive at this conclusion, the authors have used data from the Danish Colorectal Cancer Group Database as well as administrative data from the Danish National Health Service. The results of the manuscript are straight forward and the conclusion seems to offer important insights regarding clinical management. Nonetheless, several points would need clarification.
Major points 1. As noted in Table 1 , patients not prescribed with RAAS blockers are tended to be younger, not hypertensive, and without known CKD. Although the authors have included these factor as covariates in the multivariate analyses, further means to ensure that the presented findings are not a result of these confounding factors would be needed. If possible, propensity score matching the patients for each group would improve the integrity of the results. Response: We have now computed propensity scores predicting the probability of developing AKI conditional on the observed baseline covariates, using multivariate logistic regression. Thus, two propensity score matched analyses were performed in order to analyze both former and current users: 1) Former vs. non-users of ACE-I/ARB 2) Current vs. non-user of ACE-I/ARB The propensity score matched analyses aimed to match each AKI patient with the patient without AKI, with the nearest propensity score within a maximum caliper range of ±0.025 and no replacement. In analysis 1) we were able to match 91 (56.5%) of 161 patients with AKI to a patient without AKI. In analysis 2) we were able to match 283 (50.7%) of 558 patients with AKI to a patient without AKI. In both analyses, covariates were adequately balanced after propensity score matching. The results support our hypothesis that the increased risk of AKI in former and current users of ACE-I/ARB compared with non-users, is merely due to the underlying indication, than the drug effect (Table  S5 ). The propensity score matched analysis results in a comparison that includes patients who are more similar than the entire cohort. However, the results should be interpreted with caution as the statistic precision is reduced, which is also reflected by the widening of the confidence intervals. Information regarding the propensity score matched analyses have been provided in the manuscript on page 9 in the 2nd paragraph: "Moreover, propensity score matched analyses were conducted." And on page 12 in the results, sensitivity analyses with the phrasing: "Estimated from the propensity score matched analyses were close to unity (Supplementary, Table S5 and S6)."
2. AKI incidence would be affected by the type and presence of stoma formation. Would it be possible for this data to be included in the analyses? Response: This information would definitely be relevant. We have information on whether the patients had stoma formation, but unfortunately no information regarding the output of these. Loop-ileostomies can produce large amounts of stoma output during the first 7 days which could lead to dehydration/hypovolemia and thus an increased risk of AKI. To evaluate the extent to which stoma formation may have affected AKI incidence, we have repeated the analysis restricted to the patients without stoma formation. We found no major difference in our estimates compared with the results of the original analysis. Results are included in supplementary table S7 as seen below. 3. Did the baseline eGFR differ among the groups? If not, please consider including eGFR as a confounding covariate in the analyses.
We have now provided the median, interquartile range eGFR for each exposure group in Table 1 on page 11 in the manuscript. We adjusted for eGFR as dichotomous variable as the CKD variable was based on baseline eGFR. We do not expect that the impact of eGFR is linear, and it should therefore not be included as a continuous variable in the model. Given the relatively low number of outcomes, we can hardly expand the model further, e.g., by including eGFR as a categorical variable. If requested, we will of course reconsider whether replacement of other variables would be possible to allow better adjustment of eGFR.
4. Could there be a possibility of patients receiving ACEi/ARB prescriptions for more than 90 days? Is the number or prescription days restricted in Denmark? Response: The rationale for this definition was that ACE-I/ARBs typically are prescribed in packages of no more than 90-100 tablets in Denmark and is usually administered once a day. Nevertheless, we cannot exclude that some patients have longer prescriptions. Thus, we will misclassify current ACE-I/ARB users as former use, which will bias our results towards the null. Any potential bias is expected to be minimal, as 90% of the patients in our cohort either collected their medication with 30-day or 90-day intervals.
5. In figure 3 , significance for interaction should be provided for each subgroup.
Response: We provided information on biological interaction (effect measure modification) through stratification by subgroups of the cohort. To avoid confusion, we prefer not to do significance testing of statistical interaction, which describes a mathematical model of a specific data set where the magnitude depends on the choice of measure and scale of measurement. Thus, factors that show biological interaction will not necessarily show statistical interaction. Instead of statistical significance testing, we quantified the precision of our results by the width of the confidence intervals. To avoid reducing inference to dichotomy, based on statistical instead of clinical significance, we prefer not to include P-values.
Reviewer: 2 Reviewer Name: Swapnil Hiremath Institution and Country: University of Ottawa Please state any competing interests or state 'None declared': None declared Please leave your comments for the authors below The present study uses data from the Danish colorectal cancer group database to report the association between preoperative and an angiotensin system blocker use and the risk of AKI postoperatively. They report that current and former users are at increased risk of postoperative AKI. The studies overall well done and reported cleanly, with an adequate discussion of the limitations. The following suggestions are provided to help readers put things into the proper perspective.
1. From table 1, it is obvious that former and current users of these drugs are different than nonusers. Given the numbers involved, would it be possible to consider propensity score matching as a stronger design? Residual confounding would still be a concern, however this study design with PS matching would give more confidence. It can be seen from the analysis, that the risk of AKI is about 40% higher and this is attenuated to about 15 to 20% after adjustment. Hence the question of residual confounding, as identified by the authors also, is a big one. Response: Please see response to comment 1 from reviewer 1.
2.The outcome definition is based on a change in creatinine within 7 days, which is different than the usual 48 to 72 hours. Response: Thank you for the comment. We have used the complete KDIGO criteria to define AKI requiring that the rise in creatinine showed be assumed to be within 7 days. For AKI stage 1, the absolute increase criteria is required be within 48 hours.
Though not presented, it would be interesting to see the severity of acute kidney injury among former or current users compared to nonusers. Arguably, the soft definition of AKI, which is a biochemical change, is not meaningful. See the review by Steve Coca which discusses the issue of her rising creatinine as compared to true tubular injury. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5989667/ Response: We agree that it would be of interest to include analyses focusing on the more severe AKI stages. Unfortunately, we do not have enough outcomes to provide sufficient statistical precision in an analysis to address AKI severity. We believe it is of clinical relevance to include any AKI stage, as we have previously shown that even AKI stage 1 has large prognostic impact in patients undergoing colorectal cancer surgery .
3. Most importantly, though the abstract and the article summary are measured in the conclusions, the interpretation section of the manuscript overreaches in the recommendation. In the absence of any randomized controlled trial, this reviewer would not put any recommendations about changing or stopping these drugs preoperatively. Stopping these drugs may have unintended consequences, including an increase in blood pressure, and decompensation of beneficial effects in patients for whom there is a strong indication to take them. Response: Thank you for the comment. It is not our intention to provide recommendation on whether to stop or continue the use of ACE-I/ARB before CRC surgery. The intention was to recommend recognizing this population of CRC surgery patients as having an increased risk of developing AKI. We have clarified this in the interpretation section of the manuscript on page 16 (last paragraph) -page 17. "Thus, patients being users of ACE-I/ARB represent a group of CRC surgery patients at increased risk of AKI, and increased awareness of postoperative AKI among ACE-I/ARB users may be needed, to modify the clinical course of AKI and potentially improving the prognosis for a considerable number of CRC surgery patients."
Minor issues: 4. The very first sentence in the introduction about the role of ACE inhibitors is a bit of an understatement, considering the hemodynamic effects of these drugs. Response: Thank you for this suggestion. We have revised the sentence (page 4) to better reflect the frequency and hemodynamic effects of these drugs: "Angiotensin-converting enzyme inhibitors (ACE-I) and angiotensin-receptor blockers (ARB) are widely prescribed drugs targeting the regulation of water and salt retention in the kidneys leading to hemodynamic effects [1]."
5. In the second paragraph of the introduction, with the sentence starting "AKI is defined as", it would be more useful to also state the definition of AKI used in the citation #5. Response: We agree and have corrected this in the manuscript on page 4, second paragraph. "AKI is defined as a sudden decline in the excretory function of the kidneys kidney function and occurs in around 20% of patients undergoing CRC surgery This is a straightforward and well-written paper that looks at the association between use of ACEI/ARB before colorectal surgery and the development of AKI. There are limitations, but these are inherent to using observational data to address this question and are understood by the authors I have relatively minor comments to make where I think the authors could strengthen the paper. 1. 'PCr' suggests protein: creatinine ratio to me. Is there a reason why they can't just say 'creatinine'? Response: Thank you for this suggestion to clarify. We have changed 'PCr' to 'creatinine' throughout the manuscript. 2. If no baseline creatinine was available I think the authors imputed it "If neither measurement was available, it was estimated using the Modification of Diet in Renal Disease (MRDR) formula as recommended by the RIFLE, AKIN and KDIGO consensus criteria [6, 26] ." As I suspect the authors know this practice is not widely accepted in AKI research (eg https://onlinelibrary.wiley.com/doi/abs/10.1111/apha.12763). I would imagine that not having a baseline creatinine is strongly associated with the covariates. I think they dropped these patients with imputed baseline in their complete case analysis and reassuringly this shows similar outcomes. My preference would be to not include these patients at all in the main analysis as this is least prone to misclassification, and use this 'imputed' analysis as a secondary analysis. However, I don't feel it is necessary to insist on this but the authors need to be explicit about what the GFR they back calculated was, how many patients this involved, and at least do a sensitivity analysis dropping these patients (separately from dropping those with imputed baseline CKD status). Response: We agree that patients undergoing CRC surgery are expected to have preoperative creatinine measurements, but there are some patients referred to surgery from areas not covered by the laboratory database. Therefore, we do not expect any major difference in patient characteristics in patients with and without a creatinine measurement. In addition, baseline creatinine was missing, and therefore estimated by the MDRD equation, in 516 (5%) of the patients. We are aware of the ongoing discussion about the definition of baseline creatinine in AKI research, , but in the current cohort we do not believe it should be a major problem. This is confirmed by similar results in imputed and complete case analyses. Thus, we prefer to keep the analysis with imputed creatinine as the main analysis and the complete case analysis as a secondary analysis. We are of course willing to reconsider if requested by the editor. To further address the issue, we now provided an analysis restricted to the patients with at least one baseline creatinine measurement in supplementary table S8. We found similar RR estimates and 7-day incidence proportions. (0-59, 60-69, 70-79, ≥80 years) , alcohol, body mass index, cancer type, chronic kidney disease, diabetes mellitus, heart disease, hypertension, liver disease, obstructive pulmonary disease, sex, smoking, and urgency of surgery.
3. Similarly, "Chronic kidney disease (CKD), a strong predictor for AKI [6] , was identified using PCr measurements from LAKBA [22] and defined as an estimated glomerular filtration rate (eGFR) <60 ml/min/1.73 m2 lasting at least three months within two years before CRC surgery." Here my preference would be to use impaired eGFR as the adjusting variable as there is less bias than for people who have two measures of creatinine to define CKD -and use CKD as the authors have defined it as a sensitivity analysis. Again, not insisting the authors do this, but is it correct that 80% had 2 measures? How many had only 1? Response: We appreciate the suggestion. It is correct that 80% had 2 or more measurements while 5% had only one measurement. As we would only have a few more patients with data if we relied on one measurement, we prefer to keep the stricter criteria including at least two lowered eGFR measurements as this is less prone to fluctuations in creatinine level and this is in accordance with the eGFR definition of CKD by the KDIGO CKD guideline . 4. "Multiple imputations of the covariates (CKD, smoking, BMI, weekly alcohol intake) with missing data (~20%) were performed using the mi impute chained procedure in Stata 13.1 to create five imputed datasets" Please could the authors state the assumptions they used to do the imputation and justify it briefly. I would say that MCAR does not apply and MAR is tenuous. However, the complete case analysis is reassuring. As above, the authors should show the no baseline creatinine to define AKI and no CKD status (and the no imputed data) as separate analyses in the supp appendix, both with the numbers included. Response: Thank you for pointing out the need for the assumptions to be stated. A description has been added to the manuscript under statistical methods on page 9, second paragraph. "We expected missing data to be missing at random (MAR), since there would be some dependency between missing covariates and the risk of developing AKI." As mentioned above a restricted analysis has been provided in the (0-59, 60-69, 70-79, ≥80 years) , alcohol, body mass index, cancer type, chronic kidney disease, diabetes mellitus, heart disease, hypertension, liver disease, obstructive pulmonary disease, sex, smoking, and urgency of surgery.
5.
What is lovely about your study is that you show that it is the indication for the ACEI/ARB, or the pathology associated with that indication, that causes the AKI, not the drug itself (as the association of AKI is basically the same for users and ex-users). I would say this directly rather than 'We cannot rule out that confounding by indication may also have contributed to the results.'. Similarly, you state 'we cannot rule out that the lack of difference in association for current and former user may be explained by unmeasured confounding by indication and residual confounding. For example, we lack data on blood pressure, fluid balance and administration, and timing of other postoperative complications." This is not clear and it would be good to give a direct example of how confounding would cause AKI. However, I would argue that it is not confounding, it is a causal effect, just not due to the drug. Response: Thank you very much for highlighting this. We have changed the wording to be more direct and have provided an example as to why intraoperative blood pressure may be a confounder in the manuscript on page 15, first paragraph. "Despite extensive adjustment for potential confounders including comorbidities and lifestyle factors, we cannot rule out that the lack of difference in association for current and former users may be explained by residual confounding or by unmeasured confounding by indication [46] from the lack of data on blood pressure, fluid balance and administration, the timing of other postoperative complications and did only partly adjust for preoperative eGFR . For example, during anesthesia a lower mean arterial pressure (MAP) is accepted for healthy patients, whereas patients treated for hypertension are typically held at a MAP 5-10mmHg higher as well as for shorter periods due the potentially impaired autoregulation. On the other hand, ACE-I/ARB users potentially have even higher risk of AKI than found in this study, due to preventive actions taken based on the indication, which we
